[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy].
Male
Female
Humans
Infant
Child, Preschool
Child
Adolescent
Young Adult
Adult
Receptors, Chimeric Antigen
Japan
Transfusion Medicine
Receptors, Antigen, T-Cell
Immunotherapy, Adoptive
/ methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Cell- and Tissue-Based Therapy
Antigens, CD19
B-cell acute lymphoblastic leukemia
Chimeric antigen receptor-T cell therapy
Manufacturing failure
Tisagenlecleucel
Journal
[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
6
6
2023
pubmed:
5
6
2023
entrez:
4
6
2023
Statut:
ppublish
Résumé
The frequency of the manufacturing failure of chimeric antigen receptor (CAR)-T cell therapy in clinical practice is unknown. To clarify the current state of how likely CAR-T cell production is to succeed or fail for B-cell acute lymphoblastic leukemia (B-ALL), we analyzed cases in which the production of tisagenlecleucel was performed for patients with B-ALL at 15 facilities in Japan from October 2019 to March 2022. Total 81 patients (47 males and 34 females) were analyzed. The median age at apheresis was 13 years (1-25) with a median number of prior treatments of 4 (1-9). The numbers of patients with histories of allogeneic transplantation, inotuzumab ozogamicin, or blinatumomab treatments were 51 (63.0%), 26 (32.1%), and 37 (45.7%), respectively. The median blast percentage and CD3
Identifiants
pubmed: 37271521
doi: 10.11406/rinketsu.64.331
doi:
Substances chimiques
tisagenlecleucel
Q6C9WHR03O
Receptors, Chimeric Antigen
0
Receptors, Antigen, T-Cell
0
Antigens, CD19
0
Types de publication
English Abstract
Journal Article
Langues
jpn
Sous-ensembles de citation
IM